- Raised $330k funding round, Jul 2023
- Raised $550k funding round, Aug 2022
- Raised $1.5M funding round, Dec 2020
About
PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor technology, the company is focused on becoming a leading producer of GMP-standard ibogaine and psilocybin for use by target customers in the development and production of psychedelic- and ibogaine-based pharmaceuticals, food supplements, and other products. PsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine. Ibogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.
Funding history · 3 rounds · $2.4M total
Q&A
- What is PsyRx's primary focus in drug development?
- PsyRx is a pharmaceutical R&D company focused on developing biological API psilocybin and ibogaine using biological bioreactor technology, aiming to become a leading producer of GMP-standard versions of these compounds.
- What is PsyRx's vision for a new antidepressant drug?
- PsyRx aims to develop a revolutionary antidepressant drug that combines ibogaine with existing approved antidepressants, with the goal of reducing side effects and improving efficacy for the treatment of depression and addiction.
- When was PsyRx founded?
- PsyRx was founded in October 2019.
- What is the total amount of funding PsyRx has raised to date?
- PsyRx has raised a total of $2,380,000 USD.
- When was PsyRx's most recent funding round?
- PsyRx's most recent funding round occurred in July 2023, raising $330,000 USD.
- Who are the co-founders of PsyRx?
- The co-founders of PsyRx include Asher Holzer, Itay Hecht, and Kobi Buxdorf.
- What is PsyRx's current product stage?
- PsyRx's product is currently in the clinical trial stage.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | psyrx.co/ |
|---|---|
| linkedin.com/company/79826212 | |
| facebook.com/psyrxpsychedelics |
Identifiers & details
| Founded | 2019-10 |
|---|---|
| Employees (exact) | 5 |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | psyrx.co |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|